Progress and prospects: Genetic engineering in xenotransplantation

Gene Therapy

Volumn 15, Issue 18, 2008, Pages 1247-1256

  Le Bas Bernardet, S ^a,b,c   Anegon, I ^a,b,c   Blancho, G ^a,b,c  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALPHA 1,3 GALACTOSYLTRANSFERASE; BETA 2 MICROGLOBULIN; BETA GALACTOSIDASE; CD28 ANTIGEN; CD39 ANTIGEN; CD59 ANTIGEN; CD94 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; ENDO BETA GALACTOSIDASE C; GAMMA INTERFERON; HLA E ANTIGEN; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 10; INTERLEUKIN 4; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE COFACTOR PROTEIN; N ACETYLGLUCOSAMINYLTRANSFERASE; NATURAL KILLER CELL RECEPTOR NKG2A; PROTEIN C; REGULATOR PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; THROMBIN; THROMBOMODULIN;

ANTIGEN EXPRESSION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELLULAR IMMUNITY; CROSS BREEDING; CYTOTOXICITY; DNA MODIFICATION; ENZYME ACTIVITY; EXPERIMENTAL PIG; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE ISOLATION; GENE TRANSFER; GENETIC ENGINEERING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; RNA INTERFERENCE; THROMBOSIS; VIRAL GENE DELIVERY SYSTEM; VIRUS TRANSMISSION; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; GENETIC ENGINEERING; GRAFT REJECTION; HUMANS; SWINE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; PORCINE ENDOGENOUS RETROVIRUS; SUIDAE; SUS;

EID: 51049087302     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.119     Document Type: Review

References (36)

1. Watanabe S, Misawa M, Matsuzaki T, Sakurai T, Muramatsu T, Yokomine TA et al. Production and characterization of transgenic mice systemically expressing endo-beta-galactosidase C. Glycobiology 2008; 18: 9-19.
2. Matsunami K, Miyagawa S, Nakagawa K, Otsuka H, Shirakura R. Molecular cloning of pigGnT-I and I.2: An application to xenotransplantation. Biochem Biophys Res Commun 2006; 343: 677-683.
3. Milland J, Christiansen D, Lazarus BD, Taylor SG, Xing PX, Sandrin MS. The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene. J Immunol 2006; 176: 2448-2454.
4. Nottle MB, Beebe LF, Harrison SJ, McIlfatrick SM, Ashman RJ, O'Connell PJ et al. Production of homozygous alpha-1,3-galactosyltransferase knockout pigs by breeding and somatic cell nuclear transfer. Xenotransplantation 2007; 14: 339-344.
5. Ezzelarab M, Cortese-Hassett A, Cooper DK, Yazer MH. Extended coagulation profiles of healthy baboons and of baboons rejecting GT-KO pig heart grafts. Xenotransplantation 2006; 13: 522-528.
6. Hara H, Ezzelarab M, Rood PP, Lin YJ, Busch J, Ibrahim Z et al. Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation 2006; 13: 357-365.
7. Zahorsky-Reeves JL, Kearns-Jonker MK, Lam TT, Jackson JR, Morris RE, Starnes VA et al. The xenoantibody response and immunoglobulin gene expression profile of cynomolgus monkeys transplanted with hDAF-transgenic porcine hearts. Xenotransplantation 2007; 14 135-144.
8. Deppenmeier S, Bock O, Mengel M, Niemann H, Kues W, Lemme E et al. Health status of transgenic pigs expressing the human complement regulatory protein CD59. Xenotransplantation 2006; 13: 345-356.
9. Poling J, Oezkur M, Kogge K, Mengel M, Niemann H, Winkler M et al. Hyperacute rejection in ex vivo-perfused porcine lungs transgenic for human complement regulatory proteins. Transpl Int 2006; 19 225-232.
10. Wu G, Pfeiffer S, Schroder C, Zhang T, Nguyen BN, Kelishadi S et al Coagulation cascade activation triggers early failure of pig hearts expressing human complement regulatory genes. Xenotransplantation 2007; 14: 34-47.
11. Liu D, Kobayashi T, Onishi A, Furusawa T, Iwamoto M, Suzuki S et al Relation between human decay-accelerating factor (hDAF) expression in pig cells and inhibition of human serum anti-pig cytotoxicity: Value of highly expressed hDAF for xenotransplantation. Xenotransplantation 2007; 14: 67-73.
12. Smolenski RT, Forni M, Maccherini M, Bacci ML, Slominska EM, Wang H et al. Reduction of hyperacute rejection and protection of metabolism and function in hearts of human decay accelerating factor (hDAF)-expressing pigs. Cardiovasc Res 2007; 73: 143-152.
13. Manzi L, Montano R, Abad MJ, Arsenak M, Romano E, Taylor P. Expression of human soluble complement receptor 1 by a pig endothelial cell line inhibits lysis by human serum. Xenotransplantation 2006; 13: 75-79.
14. Godwin JW, Fisicaro N, d'Apice AJ, Cowan PJ. Towards endothelial cell-specific transgene expression in pigs: Characterization of the pig ICAM-2 promoter. Xenotransplantation 2006; 13: 514-521.
15. Dwyer KM, Mysore TB, Crikis S, Robson SC, Nandurkar H, Cowan PJ et al The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation 2006; 82: 428-432.
16. Mitsuhashi N, Fischer-Lougheed J, Shulkin I, Kleihauer A, Kohn DB, Weinberg KI et al. Tolerance induction by lentiviral gene therapy with a nonmyeloablative regimen. Blood 2006; 107: 2286-2293.
17. Fischer-Lougheed JY, Tarantal AF, Shulkin I, Mitsuhashi N, Kohn DB, Lee CC et al. Gene therapy to inhibit xenoantibody production using lentiviral vectors in non-human primates. Gene Therapy 2007; 14 49-57.
18. Mulley WR, Wee JL, Christiansen D, Milland J, Ierino FL, Sandrin MS. Lentiviral expression of CTLA4Ig inhibits primed xenogeneic lymphocyte proliferation and cytokine responses. Xenotransplantation 2006; 13: 248-252.
19. Jeon DH, Oh K, Oh BC, Nam DH, Kim CH, Park HB et al. Porcine PD-L1: Cloning, characterization, and implications during xenotransplantation. Xenotransplantation 2007; 14: 236-242.
20. Lilienfeld BG, Crew MD, Forte P, Baumann BC, Seebach JD. Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cell-mediated cytotoxicity. Xenotransplantation 2007; 14: 126-134.
21. Dieckhoff B, Karlas A, Hofmann A, Kues WA, Petersen B, Pfeifer A et al. Inhibition of porcine endogenous retroviruses (PERVs) in primary porcine cells by RNA interference using lentiviral vectors. Arch Virol 2007; 152: 629-634.
22. Dieckhoff B, Petersen B, Kues WA, Kurth R, Niemann H, Denner J. Knockdown of porcine endogenous retrovirus (PERV) expression by PERV-specific shRNA in transgenic pigs. Xenotransplantation 2008; 15: 36-45.
23. Yang H, Zhong R. Satellite Symposium on Xenotransplantation-D. Session 'Renal Transplantation'-(1) The role of anti-non-Gal antibodies in xenograft rejection in a pig-to-baboon kidney transplantation model. Xenotransplantation 2007; 14: 184-186.
24. Cowan PJ. Coagulation and the xenograft endothelium. Xenotransplantation 2007; 14: 7-12.
25. Roussel JC, Moran CJ, Salvaris EJ, Nandurkar HH, d'Apice AJ, Cowan PJ. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008; 8 1101-1112.
26. Kitchens WH, Uehara S, Chase CM, Colvin RB, Russell PS, Madsen JC. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 2006; 81: 811-817.
27. Lilienfeld BG, Garcia-Borges C, Crew MD, Seebach JD. Porcine UL16-binding protein 1 expressed on the surface of endothelial cells triggers human NK cytotoxicity through NKG2D. J Immunol 2006; 177: 2146-2152.
28. Pierson RN. Primate T-cell responses to porcine antigens: Implications for clinical xenotransplantation. Xenotransplantation 2006; 13 14-18.
29. Sprangers B, Waer M, Billiau AD. Xenotransplantation: Where are we in 2008? Kidney Int 2008; 74: 14-21.
30. Cooper DK, Dorling A, Pierson III RN, Rees M, Seebach J, Yazer M et al. Alpha1,3-galactosyltransferase gene-knockout pigs for xenotransplantation: Where do we go from here? Transplantation 2007; 84: 1-7.
31. Tai HC, Ezzelarab M, Hara H, Ayares D, Cooper DK. Progress in xenotransplantation following the introduction of gene-knockout technology. Transpl Int 2007; 20: 107-117.
32. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Grone HJ. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci USA 2007; 104: 5977-5982.
33. Sandrin MS. Gal knockout pigs: Any more carbohydrates? Transplantation 2007; 84: 8-9.
34. d'Apice AJ, Cowan PJ. Building on the GalKO platform. Transplantation 2007; 84: 10-11.
35. Salvaris EJ, Harrison S, Beebe LF, Dwyer KM, Crikis S, Hawthorne WJ et al. Generation of a Gal knockout pig expressing human CD39. Xenotransplantation 2007; 14: 417-418.
36. Petersen B, Lucas-Hahn A, Lemme E, Hermann D, Barg-Kues B, Carnwath JW et al. Production and characterization of pigs transgenic for human thrombomodulin. Xenotransplantation 2007; 14: 371.